Short Interest in Daiichi Sankyo Company, Limited (OTCMKTS:DSNKY) Expands By 6,475.0%

Daiichi Sankyo Company, Limited (OTCMKTS:DSNKY) was the target of a significant growth in short interest in the month of March. As of March 31st, there was short interest totalling 184,100 shares, a growth of 6,475.0% from the March 15th total of 2,800 shares. Based on an average daily trading volume, of 593,300 shares, the short-interest ratio is presently 0.3 days. Approximately 0.0% of the company’s shares are short sold.

Daiichi Sankyo Trading Down 1.3 %

Shares of OTCMKTS DSNKY traded down $0.29 during midday trading on Monday, hitting $21.88. The company’s stock had a trading volume of 477,823 shares, compared to its average volume of 269,018. Daiichi Sankyo has a 12-month low of $20.92 and a 12-month high of $42.48. The company has a current ratio of 2.77, a quick ratio of 2.11 and a debt-to-equity ratio of 0.06. The firm has a market cap of $41.75 billion and a P/E ratio of 25.44. The business’s 50 day moving average is $23.84 and its two-hundred day moving average is $27.89.

Daiichi Sankyo (OTCMKTS:DSNKY) last released its earnings results on Friday, January 31st. The company reported $0.22 earnings per share for the quarter. Daiichi Sankyo had a return on equity of 14.53% and a net margin of 13.62%. As a group, equities research analysts expect that Daiichi Sankyo will post 0.73 EPS for the current year.

About Daiichi Sankyo

Daiichi Sankyo Company, Limited manufactures, markets, and sells pharmaceutical products worldwide. The company offers Enhertu, a HER2 directed antibody drug conjugate; Turalio, a CSF-1R inhibitor; Vanflyta, a FLT3 inhibitor for the treatment of adult patients with relapsed/refractory FLT3-ITD acute myeloid leukemia; ferric carboxymaltose injection for treating anaemia; and Injectafer for the treatment for iron deficiency anaemia.